AstraZeneca Gets Lynparza US Approval For Breast Cancer Treatment

AstraZeneca Gets Lynparza US Approval For Breast Cancer Treatment

AstraZeneca Gets Lynparza US Approval For Breast Cancer Treatment

A report of the research, published in The Lancet Oncology, concluded: 'The study showed no significant difference in overall survival or distant disease-free survival between patients carrying a BRCA1 or BRCA2 mutation and patients without these mutations after a diagnosis of breast cancer'.

Breast cancer survival was the same in young women with and without faulty BRCA genes, according to a new study. "By undergoing genetic testing for BRCA mutations, we can gain critical information that will inform personalized treatment options specifically for women with this mutation".

"Fifty percent of the BRCA patients in this trial were triple negative", she said.

Ellen R. Copson, Ph.D., from the University of Southampton in the United Kingdom, and colleagues conducted a prospective cohort study involving female patients recruited from 127 hospitals in the United Kingdom who were aged 40 years or younger at first diagnosis of invasive breast cancer.

"In the longer term, risk-reducing surgery should be discussed as an option for BRCA1 mutation carriers in particular, to minimise their future risk of developing a new breast or ovarian cancer".

Matt Le Tissier: Salah is the Premier League signing of the summer
Manchester City tops the Premier League table after 22 games, with 62 points after 20 victories and two games ending with a draw. As for Man City , Pep Guardiola nearly lost their first match of the season recently during a 0-0 draw at Crystal Palace .

While it put women at an increased risk of developing breast cancer, the faulty gene did not mean they were less likely to survive.

The PARP inhibitor is now available to patients with deleterious or suspected germline BRCA-mutated (bBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.

Professor Diana Eccles, head of cancer sciences at the University of Southampton, said: "Our study is the largest of its kind, and our findings suggest that younger women with breast cancer who have a BRCA mutation have similar survival to women who do not carry the mutation after receiving treatment".

Some women have previously made a decision to take preventative measures, such as pre-emptive mastectomies, when they discover they have faulty genes.

"It can be hard for some patients to decide whether or not to have risk-reducing surgery, typically double mastectomies and removal of ovaries".

Fernando Hierro Wants Calm At Real Madrid
This inefficiency in the attack has cost Real Madrid to no end and they need to find the answers quickly to savour the season. But if there is a player you want, is available and he gives you value, I don't see it bad, but I don't have that.

'However, our findings suggest that this surgery does not have to be immediately undertaken along with the other treatment.

The agency said its approval was based on a randomized clinical trial of more than 300 advanced breast cancer patients with BRCA 1 or BRCA 2 mutations. A total of 12 per cent of the women in the study carried the BRCA mutation.

This surgery did not appear to improve their chances of survival at the 10-year mark.

Decision aids can help women clarify their personal values and preferences, for example by focusing on whether they want to avoid radiation or concentrate on preserving their breasts, said Dr. Clara Lee, a cancer researcher at The Ohio State University Wexner Medical Center in Columbus.

China Dec imports from North Korea down 81.6 pct y/y - China customs
Economists had expected China's trade surplus to have narrowed to $37 billion in December from November's $40.21 billion. For 2017, China's imports from North Korea dropped 33 percent to $1.72 billion, the lowest value in at least four years.

Related news